Literature DB >> 22996404

Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.

Pran Kishore Deb1, Anuradha Sharma, Poonam Piplani, Raghuram Rao Akkinepally.   

Abstract

The reversible inhibition of acetylcholinesterase (AChE) has become a promising target for the treatment of Alzheimer's disease (AD) which is mainly associated with low in vivo levels of acetylcholine (ACh). The availability of AChE crystal structures with and without a ligand triggered the effort to find a structure-based design of acetylcholinesterase inhibitors (AChEIs) for AD. The major problem observed with the structure-based design was the feeble robustness of the scoring functions toward the correlation of docking scores with inhibitory potencies of known ligands. This prompted us to develop new prediction models using the stepwise regression analysis based on consensus of different docking and their scoring methods (GOLD, LigandFit, and GLIDE). In the present investigation, a dataset of 91 molecules belonging to 9 different structural classes of heterocyclic compounds with an activity range of 0.008 to 281,000 nM was considered for docking studies and development of AChE-specific 3D-QSAR models. The model (M1) developed using consensus of docking scores of scoring functions viz. Glide score, Gold score, Chem score, ASP score, PMF score, and DOCK score was found to be the best (R(2) = 0.938, Q(2) = 0.925, R(pred)(2) = 0.919, R(2)m((overall)) = 0.936) compared to other consensus models. Docking studies revealed that the molecules with proper alignment in the active site gorge and the ability to interact with all the crucial amino acid residues, in particular by forming π-π stacking interactions with Trp84 at the catalytic anionic site (CAS) and Trp279 at peripheral anionic site (PAS), showed augmented potencies with consequent improvement in patient cognition and reduced the formation of senile plaques associated with AD. Further, the descriptors that signify the association of the ligands with the receptor as well as ADME properties of the ligands were also analyzed by means of the set of ligands that have been pre-positioned with respect to a receptor after docking analysis and considered as independent variables to generate a linear model (M3 and M4) using a stepwise multiple linear regression method to get additional insight into the physicochemical requirements for effective binding of ligands with AChE as well as for prediction of AChE inhibition. The developed AChE-specific prediction models (M1-M4) satisfactorily reflect the structure-activity relationship of the existing AChEIs and have all the potential to facilitate the process of design and development of new potent AChEIs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996404     DOI: 10.1007/s11030-012-9394-x

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  45 in total

1.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.

Authors:  G Kryger; I Silman; J L Sussman
Journal:  Structure       Date:  1999-03-15       Impact factor: 5.006

2.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  General and targeted statistical potentials for protein-ligand interactions.

Authors:  Wijnand T M Mooij; Marcel L Verdonk
Journal:  Proteins       Date:  2005-11-01

Review 4.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

5.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Authors:  M D Eldridge; C W Murray; T R Auton; G V Paolini; R P Mee
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

6.  Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.

Authors:  María Isabel Fernández-Bachiller; Concepción Pérez; Gema C González-Muñoz; Santiago Conde; Manuela G López; Mercedes Villarroya; Antonio G García; María Isabel Rodríguez-Franco
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

7.  Molecular modeling evaluation of non-steroidal aromatase inhibitors.

Authors:  Bheemanapalli Lakshmi Narayana; Deb Pran Kishore; Chadrasekaran Balakumar; Kaki Venkata Rao; Rajwinder Kaur; Akkinepally Raghuram Rao; Javali Narashima Murthy; Muttineni Ravikumar
Journal:  Chem Biol Drug Des       Date:  2012-02-23       Impact factor: 2.817

Review 8.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

Authors:  Ana Castro; Ana Martinez
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

9.  Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.

Authors:  Maria Laura Bolognesi; Manuela Bartolini; Andrea Cavalli; Vincenza Andrisano; Michela Rosini; Anna Minarini; Carlo Melchiorre
Journal:  J Med Chem       Date:  2004-11-18       Impact factor: 7.446

Review 10.  Amyloid-cholinesterase interactions. Implications for Alzheimer's disease.

Authors:  Nibaldo C Inestrosa; Margarita C Dinamarca; Alejandra Alvarez
Journal:  FEBS J       Date:  2008-01-17       Impact factor: 5.542

View more
  12 in total

1.  A mechanism-based 3D-QSAR approach for classification and prediction of acetylcholinesterase inhibitory potency of organophosphate and carbamate analogs.

Authors:  Sehan Lee; Mace G Barron
Journal:  J Comput Aided Mol Des       Date:  2016-04-07       Impact factor: 3.686

Review 2.  In Silico Studies in Drug Research Against Neurodegenerative Diseases.

Authors:  Farahnaz Rezaei Makhouri; Jahan B Ghasemi
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

3.  Chemical Constituents and their Antioxidant, Anti-Inflammatory and Anti-Acetylcholinesterase Activities from Pholidota cantonensis.

Authors:  Liang Liu; Meijia Zou; Kewu Zeng; Xiaoming Ye; Runkun Wang; Wei Wang; Xianwen Zhang
Journal:  Plant Foods Hum Nutr       Date:  2021-02-23       Impact factor: 3.921

4.  Conformational analysis and parallel QM/MM X-ray refinement of protein bound anti-Alzheimer drug donepezil.

Authors:  Zheng Fu; Xue Li; Yipu Miao; Kenneth M Merz
Journal:  J Chem Theory Comput       Date:  2013-02-18       Impact factor: 6.006

5.  In silico studies in probing the role of kinetic and structural effects of different drugs for the reactivation of tabun-inhibited AChE.

Authors:  Rabindranath Lo; Nellore Bhanu Chandar; Manoj K Kesharwani; Aastha Jain; Bishwajit Ganguly
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

6.  Probing the origins of human acetylcholinesterase inhibition via QSAR modeling and molecular docking.

Authors:  Saw Simeon; Nuttapat Anuwongcharoen; Watshara Shoombuatong; Aijaz Ahmad Malik; Virapong Prachayasittikul; Jarl E S Wikberg; Chanin Nantasenamat
Journal:  PeerJ       Date:  2016-08-09       Impact factor: 2.984

7.  3D-QSAR and Molecular Docking Studies on the TcPMCA1-Mediated Detoxification of Scopoletin and Coumarin Derivatives.

Authors:  Qiu-Li Hou; Jin-Xiang Luo; Bing-Chuan Zhang; Gao-Fei Jiang; Wei Ding; Yong-Qiang Zhang
Journal:  Int J Mol Sci       Date:  2017-06-27       Impact factor: 5.923

8.  Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.

Authors:  Xiaocong Pang; Hui Fu; Shilun Yang; Lin Wang; Ai-Lin Liu; Song Wu; Guan-Hua Du
Journal:  Molecules       Date:  2017-07-26       Impact factor: 4.411

9.  Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual‑acting cholinesterase inhibitor and histamine‑3 receptor antagonist.

Authors:  Xiaocong Pang; Ying Zhao; Junke Song; Song Wu; Lin Wang; Ailin Liu; Guanhua Du
Journal:  Mol Med Rep       Date:  2019-05-28       Impact factor: 2.952

10.  Dual binding site and selective acetylcholinesterase inhibitors derived from integrated pharmacophore models and sequential virtual screening.

Authors:  Shikhar Gupta; C Gopi Mohan
Journal:  Biomed Res Int       Date:  2014-06-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.